Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2023 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder

Promissory note extends cash runway into early Q3 2023 OLPRUVA™ expected to be available by prescription in the U.S. beginning July 5th NEWTON, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Acer...
May 15, 2023 17:10 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update

NEWTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
May 01, 2023 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule

Availability: OLPRUVA™ drug in channel now anticipated in mid-June 2023 Awareness: 70% of metabolic treatment providers surveyed by Acer at SIMD Annual Meeting indicated an interest in treating at...
March 27, 2023 16:01 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update

NEWTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
March 22, 2023 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes

NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
March 22, 2023 08:00 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
March 17, 2023 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial

NEWTON, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
March 15, 2023 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program Update

Results to be presented from a survey designed to quantify treatment preferences of healthcare providers for Urea Cycle Disorders (UCDs) OLPRUVA™ preliminary launch activities progressing; building...
February 13, 2023 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
January 09, 2023 08:30 ET | Source: Acer Therapeutics Inc.

Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones

NEWTON, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and...